Boone Capital Management
ATLANTA, GAfiles as BOONE CAPITAL MANAGEMENT LLC
$428m in 16 US stocks at the end of 30 June 2026. The top 10 are 83.0% of the money. It changed about 28.7% of the portfolio this quarter.
Value
$428m
Stocks
16
Top 10 share
83.0%
Turnover
28.7%
What changed this quarter
New
Bought for the first time this quarter.
- VestisVSTS6.5% of the fund
- Pennant GroupPNTG4.5% of the fund
- Monte Rosa TherapeuticsGLUE3.5% of the fund
- Tango TherapeuticsTNGX3.3% of the fund
- Kymera TherapeuticsKYMR3.0% of the fund
- Cullinan TherapeuticsCGEM3.0% of the fund
- Adlai NortyeANL0.7% of the fund
Added
Bought more of a stock they already held.
- TeleflexTFX11.5% of the fund+39%
- Cigna GroupCI10.3% of the fund+16%
- Ionis PharmaceuticalsIONS9.6% of the fund+4%
- UnitedHealth GroupUNH8.6% of the fund+12%
- Biomarin PharmaceuticalBMRN7.8% of the fund+6%
- Guardian Pharmacy ServicesGRDN7.0% of the fund+13%
- BridgeBio PharmaBBIO5.9% of the fund+48%
- Kodiak SciencesKOD3.4% of the fund+34%
Cut
Sold some of their stake.
None this quarter.
Sold out
Sold their entire stake.
- MedtronicMDT-100%
- AstrazenecaAZN-100%
- Avanos MED-100%
- Tenax TherapeuticsTENX-100%
Holdings
- Adlai NortyeANL
- Share
- 0.7%
- Value
- $3m
- Shares
- 258,390
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| TeleflexTFX | 11.5% | $49m | 387,388 | +39% |
| Mirum PharmaceuticalsMIRM | 11.4% | $49m | 415,641 | Held |
| Cigna GroupCI | 10.3% | $44m | 159,290 | +16% |
| Ionis PharmaceuticalsIONS | 9.6% | $41m | 519,977 | +4% |
| UnitedHealth GroupUNH | 8.6% | $37m | 88,687 | +12% |
| Biomarin PharmaceuticalBMRN | 7.8% | $33m | 583,219 | +6% |
| Guardian Pharmacy ServicesGRDN | 7.0% | $30m | 711,939 | +13% |
| VestisVSTS | 6.5% | $28m | 1,900,140 | New |
| BridgeBio PharmaBBIO | 5.9% | $25m | 339,720 | +48% |
| Pennant GroupPNTG | 4.5% | $19m | 515,818 | New |
| Monte Rosa TherapeuticsGLUE | 3.5% | $15m | 615,287 | New |
| Kodiak SciencesKOD | 3.4% | $15m | 378,010 | +34% |
| Tango TherapeuticsTNGX | 3.3% | $14m | 455,605 | New |
| Kymera TherapeuticsKYMR | 3.0% | $13m | 113,173 | New |
| Cullinan TherapeuticsCGEM | 3.0% | $13m | 704,442 | New |
| Adlai NortyeANL | 0.7% | $3m | 258,390 | New |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 83.3% since 30 June 2025.
Where the money is
Health care85.9%
Everyday goods7.0%
Industrials6.5%
Other0.7%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.